In-Depth Study on Soluble Guanylate CyclasesGC or EC 4.6.1.2-Pipeline Review, H1 2016

Soluble Guanylate CyclasesGC or EC 4.6.1.2-Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Soluble Guanylate CyclasesGC or EC 4.6.1.2-Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape 

Companies Mentioned

Bayer AG Boehringer Ingelheim GmbH Ironwood Pharmaceuticals, Inc. Mallinckrodt Plc NicOx S.A. SynZyme Technologies, LLC

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###